Calls for papers
-
A growing pharmaceutical company specializing in inhaled drug products is seeking a BS/MS level scientist with a background in inhalation or nasal formulation. They must be adept at solving complex problems and independently identifying problems.… Read more . . .
-
A number of companies that provide products and services to developers and manufacturers of inhaled and nasal drug products have been named as recipients of the 2011 Queen’s Awards for Enterprise. The Queen presents the… Read more . . .
-
According to Luitpold Pharmaceuticals, its suspension of both manufacturing at its Shirley, NY facility and distribution of products manufactured at that location, will not affect Sprix ketorolac tromethamine nasal spray. The company says that it… Read more . . .
-
A review of FDA approval times for OINDPs presented at the recent IPAC-RS conference verifies that the process has sped up considerably over the last decade. According to the poster authored by Ray Ormiston of… Read more . . .
-
GlaxoSmithKline (GSK); Barnard Castle, Co Durham Salary Range: £40,800 – £60,000 pa; Release Date: 4th April 2011; Closing Date: 29th April 2011. A vacancy exists for an Engineering Operations Manager within the Steriles and Inhalations… Read more . . .
-
The University of Michigan will license an antigen to NanoBio Corporation for development of a nasal vaccine using NanoBio’s NanoStat technology for the prevention of urinary tract infections (UTIs). The antigen works by eliminating E.… Read more . . .
-
Gilead Sciences and MicroDose Therapeutx have reached an agreement for the development and commercialization of MDT-637, a small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV). The dry powder formulation is… Read more . . .
-
NVA237, a once daily, long acting muscarinic agent (LAMA) DPI for the treatment of COPD, met its primary endpoint of improved bronchodilation compared to placebo after 12 weeks. The glycopyrronium bromide dry powder formulation was… Read more . . .
-
European specialty pharma company Axcan will acquire Mpex Pharmaceuticals and its lead candidate, Aeroquin levofloxacin inhalation solution for the treatment of Pseudomonas aeruginosa infections in CF patients, which is currently in Phase 3 trials. Axcan… Read more . . .
-
The FDA has rescheduled its end-of-review meeting with MannKind Corporation regarding Afrezza inhaled insulin for May 4, 2011. The agency had earlier cancelled the meeting, which had been scheduled for April 15, due to a… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA